Pharmacovigilance Volume Is Outpacing Drug Safety Team Capacity
The global pharmacovigilance market is expanding at a compound annual growth rate of 10.2 percent, driven by increasing drug approvals, expanding post-marketing surveillance requirements, and growing complexity of biologic and combination product safety monitoring obligations. Yet the trained drug safety associate workforce has not grown at a commensurate pace — creating a capacity gap that exposes pharma and biotech companies, as well as their PV service providers, to expedited reporting timeline failures.
The International Society of Pharmacovigilance's 2024 Workforce Analysis found that 47 percent of pharmacovigilance managers at small and mid-sized sponsors reported their teams routinely working above sustainable capacity during PSUR compilation periods. FDA and EMA expedited reporting requirements — 7-day reports for fatal or life-threatening unexpected serious adverse reactions, 15-day reports for all other unexpected SARs — create zero-tolerance compliance windows where administrative delays have direct regulatory consequences.
ICSR Case Intake Triage
Individual Case Safety Reports arrive through multiple channels: spontaneous reports from healthcare professionals and patients, literature case reports, clinical trial adverse event data, and reports from partner companies. A VA managing the ICSR intake queue performs the triage layer: logging each incoming report in the safety database case tracking system, categorizing the report by source and seriousness criteria, assigning initial time clock start dates for expedited reporting clock calculations, routing cases to the appropriate drug safety associate based on product and therapeutic area assignment, and flagging potentially fatal or life-threatening cases for immediate medical review escalation.
This triage function does not involve medical assessment — but without it, cases pile up in undifferentiated queues, expedited reporting clocks are miscalculated, and safety associates spend hours per week on intake logistics rather than case evaluation.
MedDRA Coding Coordination
The Medical Dictionary for Regulatory Activities (MedDRA) is the internationally mandated controlled vocabulary for adverse event terminology in ICSR reports and aggregate safety documents. Coding adverse events to MedDRA preferred terms requires trained coders, but the coordination logistics of coding assignment, quality review, and system entry can be managed by a VA.
A pharmacovigilance VA coordinates MedDRA coding workflows: distributing coding assignments from the ICSR queue to trained coders, tracking coding completion status, sending reminder communications for overdue coding assignments, logging coded terms in the safety database when coders provide verified outputs, and maintaining the MedDRA coding consistency log that tracks preferred term selections for recurring adverse event descriptions across the program. For organizations performing in-house MedDRA coding, this coordination reduces the administrative burden on lead coders by 30 to 40 percent.
PSUR and PBRER Compilation Support
Periodic Safety Update Reports (PSURs) and Periodic Benefit-Risk Evaluation Reports (PBRERs) are comprehensive aggregate safety documents submitted to EMA, FDA, and other health authorities on fixed calendars defined in the International Birth Date. Producing a PSUR/PBRER requires assembling safety data from multiple internal systems and synthesizing it across multiple structured report sections.
A PV VA manages compilation logistics: collecting cumulative exposure data, ICSR line listings, and serious adverse event summaries from the safety database team, organizing source documents in the PSUR/PBRER template sections, coordinating medical writing, safety physician, and regulatory review cycles with defined deadlines, tracking review comments and revisions through the sign-off process, and preparing the final document for electronic submission. This compilation coordination role is distinct from the medical assessment and signal evaluation requiring physician expertise — but without it, PSUR production timelines consistently overrun.
Signal Detection Literature Screening
Regulatory frameworks require sponsors to conduct systematic literature screening for potentially relevant safety information on marketed products and investigational compounds in active studies. This screening involves weekly or monthly searches of PubMed, Embase, and other biomedical databases using defined search strings, followed by triage of search results to identify cases or signals requiring medical review.
A PV VA manages the literature screening workflow: executing database searches on defined schedules using approved search strings, downloading and deduplicating search results, performing first-pass triage to exclude clearly irrelevant citations, logging potentially relevant citations in the literature screening tracker, distributing flagged citations to the medical safety reviewer with relevant context, and maintaining the screening audit trail required for regulatory inspection.
Drug safety consulting firms evaluating scalable administrative support can learn more at Stealth Agents, which provides virtual assistants trained in pharmacovigilance workflow support.
Regulatory Compliance Implications
FDA Warning Letters related to pharmacovigilance compliance most commonly cite failure to submit expedited reports within required timeframes and inadequate periodic safety reporting systems. Both failure modes are as much administrative as scientific — they reflect breakdowns in the operational infrastructure that gets cases identified, triaged, assessed, and submitted on time. Virtual assistant support for the administrative layer of PV operations is a direct investment in compliance system robustness.
Sources
- International Society of Pharmacovigilance Workforce Analysis, 2024
- EMA Guideline on Good Pharmacovigilance Practices (GVP) Module VI — Management and Reporting of Adverse Reactions, 2023 Update
- FDA Guidance: Postmarketing Safety Reporting for Human Drug and Biological Products, 2023
- ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER)
- MedDRA MSSO Subscription Services Utilization Report, 2024